In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers

To evaluate bropirimine for in vivo activity in rodent prostate cancer. Subcutaneously injected PAIII and Dunning MAT-LyLu rodent prostate cancer cells caused solid tumors and death in controls. Bropirimine was given on varying schedules at 250 mg./kg. by gavage, and tumor volume and survival were r...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of urology Vol. 155; no. 6; p. 2085
Main Authors Sarosdy, M F, Higdon, A L, Demoor, C A
Format Journal Article
LanguageEnglish
Published United States 01.06.1996
Subjects
Adenocarcinoma - drug therapy
Animals
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Cytosine - administration & dosage
Cytosine - analogs & derivatives
Cytosine - therapeutic use
Male
Neoplasm Transplantation
Prostatic Neoplasms - drug therapy
Rats
Rats, Inbred Strains
Time Factors
Tumor Cells, Cultured - drug effects
Online AccessGet more information

Cover

More Information
Summary:To evaluate bropirimine for in vivo activity in rodent prostate cancer. Subcutaneously injected PAIII and Dunning MAT-LyLu rodent prostate cancer cells caused solid tumors and death in controls. Bropirimine was given on varying schedules at 250 mg./kg. by gavage, and tumor volume and survival were recorded. Bropirimine prevented growth when given on the day of tumor injection and caused 95% of advanced tumors to regress completely in the PAIII model. Bropirimine caused significant growth inhibition and prolongation of survival in the MAT-LyLu model. Bropirimine has statistically significant in vivo activity against both of these rodent prostate cancer cell lines.
ISSN:0022-5347
DOI:10.1016/S0022-5347(01)66114-7